Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOMMORROW: Pioglitazone to Delay Onset of MCI due to AD
NCT01931566Phase 3Terminated
- Sponsor
- Takeda
- Start
- Aug 2013
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of pioglitazone in mild cognitive impairment due to Alzheimer's disease (3 arms), sponsored by Takeda. Primary endpoint: Time to Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease at 5 years. Started Aug 2013; status: terminated.
02
Drugs
pioglitazone
03
Conditions
mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NCT01931566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01931566.